南财智讯3月12日电，中国生物制药（01177.HK）发布自愿公告，公告基本信息：公司附属正大天晴自主研发的国家1类创新药TQB3454（IDH1抑制剂）治疗伴IDH1突变晚期胆道癌的III期临床研究（NCT05987358）完成预设期中分析，独立数据监查委员会（IDMC）确认主要终点无进展生存期（PFS）和总生存期（OS）均达到方案预设优效界值；主要内容：该研究为随机、双盲、安慰剂对照、多中心...
Source Link南财智讯3月12日电，中国生物制药（01177.HK）发布自愿公告，公告基本信息：公司附属正大天晴自主研发的国家1类创新药TQB3454（IDH1抑制剂）治疗伴IDH1突变晚期胆道癌的III期临床研究（NCT05987358）完成预设期中分析，独立数据监查委员会（IDMC）确认主要终点无进展生存期（PFS）和总生存期（OS）均达到方案预设优效界值；主要内容：该研究为随机、双盲、安慰剂对照、多中心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.